Oncolytics Biotech Inc T.ONC

Antibody-Drug-Conjugate (ADC) company reports patient death

[Noteable]

January 26, 2023 - Magenta Therapeutics’ MGTA-117 blood cancer clinical trial has gone from bad to worse. Weeks after Magenta dropped down a dose level in response to serious adverse events (SAEs), a patient has died after receiving the new, lower dose, prompting the biotech to voluntarily pause the study.

After the latest trial participant was dosed at the cohort 3 level, Magenta said the patient experienced “respiratory failure and cardiac arrest resulting in death” — or what investigators would classify as a Grade 5 serious adverse event. 

[Oncy has demonstrated that pelareorep is safe and effective with +1000 patients safely hving the drug administered intravenously]

https://www.fiercebiotech.com/biotech/after-dose-de-escalation-death-drives-magenta-pause-antibody-drug-conjugate-leukemia-trial

[ Gilead acquired ADC company Imuunomedics for US$21 Billion in September 2020 after Immunomedics reported data from a phase 1/2 study in April 2020 that showed the ADC shrank tumors in about 33% of TNBC patients who had received a median of three prior lines of treatment, with the response lasting for a median 7.7 months. It also delayed the time to tumor progression or death for a median 5.5 months and helped these heavily pretreated patients live 13.0 months]

https://www.fiercepharma.com/marketing/turbulent-immunomedics-wins-early-fda-blockbuster-nod-for-adc-triple-negative-breast

[Noteable]

November 2022 - "Antibody–drug conjugates (ADCs) may increase the risk of sepsis in cancer patients, leading to high mortality." "We identified that 973 of 2,441 (39.9%) cases had acute myeloid leukemia (AML), and 766 of 2613 (29.3%) cases on ADCs died during therapy. Time-to-onset analysis indicated ADC-related sepsis is prone to occur within a month after administration. Co

[Noteable]

August 2022 - " The complexities of ADC activity in the clinic are only now becoming recognized" Bystander death occurs when the cytotoxic payload harms cells that do not display the target antigen. The ability of an ADC to produce cytotoxicity is determined by a number of factors, including the characteristics of the target antigen's properties, the choice of an antibody, the

[Noteable]

November 2022 - Adverse Events (AEs) to Antibody-Drug-Conjugates (ADCs) most common in breast cancer. https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/adverse-events-related-antibody-drug-conjugates-most-common-breast-cancer/

[Noteable]

The ADC with the highest rate of allgrade treatment related adverse events (TRAEs) was trastuzumab deruxtecan (Enhertu) - which was part of a 2019 US$6.9 Billion co-marketing deal between Daiichi Sankyo and AstraZeneca.

[Noteable]

The analysis included reports from 169 clinical trials encompassing 22,492 patients. Multiple types of ADCs were included, and several cancer types were represented.  Overall, there were more than 600 types of adverse events reported across the trials. The overall incidence of TRAEs was 91.2%, and the incidence of grade 3 or higher TRAEs was 46.1%. The incidence of treatment discontinuation

[Lesalpes29]

8 posts from you yesterday and minus .12 cad! Investors probably don't understand your phd stuff! Fingers crossed to see a positive NR to push the SP well over the actual level. GLTAL

[jimsenior]

@Lesalpes29. The Noteable posts are valuable.  The opposition was set up and ready to go yesterday. Us longterm holders should know the pattern. This is a very tough stock to own and or trade at the best of times, and I think we have even more players now. HOLD. Good luck.

[Noteable]

August 02, 2023 -  Researchers have characterized treatment-related adverse events (TRAEs) reported in clinical trials of antibody-drug conjugates (ADCs).  Findings show that patients with breast cancer had the highest rate of all-grade TRAEs, and those with lymphoma had the highest rate of grade 3 or higher TRAEs. The ADC with the highest rate of allgrade TRAEs was trastuzumab

[fasttrack5]

And this effects ONC how?

[fox7mf]

Noteable, what's your opinion on the fireside chat today, and the fact that some are gleaning from the discussion that mBC is either on the backburner or completely dead now? 

[JohnnyYeg]

I don't see mBC as dead by any stretch of the imagination. They wouldn't have been given the oral presentation at ASCO and followed that with the KOL of renowned scientists if it was no longer a starter. But I do think they have to figure some things out with it before proceeding, and have PDAC and CRC moving fast into the limelight. Too bad there isn't a "PanCAN" for breast

[JohnnyYeg]

I don@t see mBC as dead by any stretch of the imagination. They wouldn@t have been given the oral presentation at ASCO and followed that with the KOL of renowned scientists if it was no longer a starter. But I do think they have to figure some things out with it before proceeding, and have PDAC and CRC moving fast into the limelight. Too bad there isn@t a @PanCAN@ for breast that has us in their

[Noteable]

Roche’s antibody drug conjugate (ADC) Kadcyla is up against Daiichi Sankyo’s Enhertu in metastatic breast cancer. And since Roche’s atezolizumab is being combined with pelarorep in the goblet study for pancreatic cancer, Roche would also be a suitable candidate for combining its immune checkpoint inibitor atezolizumab with pelareorep in the

[Quentin30]

Yes, but this would take us back to Phase I and saftey run-in trial Noteable. There is no longer time for that. As Matt stated, once they get approved (and they have to find a payer and run a successful Ph III first), then they will consider post approval studies with other CPOIs' This could well be funded by Roche... but that is 4 years away... it ain't gonna happen.

[Noteable]

Seagen antibody-drug conjugate (ADCs) TUKYSA A was approved in combination with other agents in previously treated metastatic HER2-positive breast cancer, including patients with brain metastases. Ongoing development programs in earlier stages of breast cancer as well as other HER2-positive cancers, including colorectal cancer, are taking place, and in 2020, Seagen granted Merck an

[Noteable]

In 2020, Seagen entered into global co-development and co-commercialization agreement with Merck for Ladiratuzumab Vedotin (LV) in breast cancer and other solid tumors. Seagen received $600 million upfront and is eligible for progress-dependent milestone payments up to $2.6 billion. Additionally, Merck made a $1 billion equity investment in Seagen.  With Merck stepping away

[Noteable]

August 18, 2023 - Seagen released Phase III results on Wednesday (August 16) for its tyrosine kinase inhibitor Tukysa (tucatinib), in combination with Genentech’s antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine), which met its primary endpoint of progression-free survival in HER-2 positive breast cancer patients. Serious adverse reactions occurred in the study in 26% of